Zevra Therapeutics Inc
ZVRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$685.14M
Close$
$-10.42
195.1% downside
Current Fair Value
195.1% downsideOvervalued by 195.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $685.14 Million |
|---|---|
| Enterprise Value | $611.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.4 |
| Beta | 0.88 |
| Outstanding Shares | 58,405,955 |
Return
| Return on Equity | 59.94% |
|---|---|
| Return on Assets | 44.28% |
| Return on Invested Capital | -3.06% |
Valuation & Multiples
| P/E Ratio | 5.45 |
|---|---|
| PEG | -0.41 |
| Price to Sales | 5.48 |
| Price to Book Ratio | 3.65 |
| Enterprise Value to Revenue | 5 |
| Enterprise Value to EBIT | -86.23 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$31.96 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$34.06 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9244▲ 127.69% |
|---|---|
| Total Calls | 1,126,300▼ 39.50% |
| Total Puts | 2,167,500▲ 79.82% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 74.69%▲ 6.51% |
|---|---|
| Total Invested | $384.55M▲ 12.51% |
| Investors Holding | 157▼ 11.00% |
ESG Score
No data
About Zevra Therapeutics Inc
24 employees
CEO: Travis Mickle KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its...